Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Calithera secures license to arginase inhibitors
January 2015
SHARING OPTIONS:

SOUTH SAN FRANCISCO, Calif.—Calithera Biosciences Inc. and Mars Symbioscience, a division of Mars Inc., have inked a global license agreement that grants Calithera exclusive worldwide rights to research, develop and commercialize Symbioscience’s portfolio of arginase inhibitors for use in healthcare, supporting Calithera’s goal of submitting an IND for an arginase inhibitor for cancer treatment by the end of 2015. Calithera will in turn make an upfront payment to Symbioscience, in addition to potential development and commercialization milestones and royalties on any approved products.
 
Susan M. Molineaux, CEO of Calithera Biosciences, said that “I am particularly excited about this agreement, because we believe we can apply our core expertise in tumor biology to rapidly advance Symbioscience’s potent and selective small-molecule arginase inhibitors into the clinic to develop a first-in-class immuno-oncology therapy for cancer patients.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.